Cellular and Molecular Life Sciences

, Volume 67, Issue 2, pp 171–177

Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity

Visions & Reflections (Minireview)

DOI: 10.1007/s00018-009-0189-x

Cite this article as:
Hahmann, C. & Schroeter, T. Cell. Mol. Life Sci. (2010) 67: 171. doi:10.1007/s00018-009-0189-x


The emerging critical implications of Rho/Rho-kinase (ROCK) signaling in neurodegenerative diseases, glaucoma, renoprotection, diabetes and cancer have sparked growing interest in the pharmacological potential of ROCK inhibitors beyond their current application in cardiovascular disease. This article discusses the therapeutic benefits of novel ROCK inhibitors in development, and highlights the recent advances in the current understanding of disease-dependent and isoform-specific functions of ROCK and their potential impact on future therapeutic strategies.


Rho-kinase ROCK ROCK1 ROCK2 Fasudil Y-27632 

Copyright information

© Birkhäuser Verlag, Basel/Switzerland 2009

Authors and Affiliations

  1. 1.Discovery Biology, Translational Research InstituteThe Scripps Research Institute, Scripps FloridaJupiterUSA

Personalised recommendations